MeiraGTx Holdings plc - Ordinary Shares (MGTX): Price and Financial Metrics

MeiraGTx Holdings plc - Ordinary Shares (MGTX): $13.59

0.22 (+1.65%)

POWR Rating

Component Grades













MGTX Stock Price Chart Interactive Chart >

Price chart for MGTX

MGTX Price/Volume Stats

Current price $13.59 52-week high $18.45
Prev. close $13.37 52-week low $11.60
Day low $13.33 Volume 45,200
Day high $13.81 Avg. volume 100,526
50-day MA $13.40 Dividend yield N/A
200-day MA $14.60 Market Cap 602.24M

MeiraGTx Holdings plc - Ordinary Shares (MGTX) Company Bio

MeiraGTx Limited develops gene therapies for acquired and inherited disorders. It offers products for neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and amyotrophic lateral sclerosis (ALS); ocular diseases, including rare inherited blindness and age-related macular degeneration (AMD); and xerostomia, a frequent and debilitating side effect of radiation treatment used in head and neck cancers. The company was founded in 2015 and is based in London, United Kingdom.

MGTX Latest News Stream

Event/Time News Detail
Loading, please wait...

MGTX Latest Social Stream

Loading social stream, please wait...

View Full MGTX Social Stream

Latest MGTX News From Around the Web

Below are the latest news stories about MeiraGTx Holdings plc that investors may wish to consider to help them evaluate MGTX as an investment opportunity.

5 Gene Therapy Stocks Back in Focus on AbbVie/Regenxbio Deal

The promising gene therapy approach is being evaluated for varied diseases, such as hemophilia, Duchenne muscular dystrophy (DMD), Parkinson's disease, eye disease, and cancer among others

Yahoo | September 14, 2021

MeiraGTx Announces Data at EURETINA 2021 Virtual Meeting Demonstrating Reversal of Disease Progression Following Treatment with AAV5-RPGR in X-Linked Retinitis Pigmentosa

LONDON and NEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced new data from subjects treated in the Phase 1/2 dose escalation phase of Study MGT009 indicating AAV5-RPGR, an investigational gene therapy in development for the treatment of X-linked retinitis pigmentosa (XLRP), reverses course of disease progression when retinal function assessed 12 months following treatment with AAV5-RPGR

Yahoo | September 9, 2021

Analysts' Revenue Estimates For MeiraGTx Holdings plc (NASDAQ:MGTX) Are Surging Higher

Shareholders in MeiraGTx Holdings plc ( NASDAQ:MGTX ) may be thrilled to learn that the analysts have just delivered a...

Yahoo | August 12, 2021

MeiraGTx Reports Second Quarter 2021 Financial and Operational Results

LONDON and NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial results for the second quarter ended June 30, 2021 and provided an update on recent progress.

Intrado Digital Media | August 11, 2021

MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Tops Revenue Estimates

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of 13.21% and 13.69%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | August 11, 2021

Read More 'MGTX' Stories Here

MGTX Price Returns

1-mo 1.49%
3-mo -12.32%
6-mo -3.69%
1-year 5.92%
3-year -0.07%
5-year N/A
YTD -10.24%
2020 -24.38%
2019 107.68%
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7972 seconds.